Skip to main content
. 2017 Dec 9;8(69):113472–113493. doi: 10.18632/oncotarget.23052

Figure 8. Quantification of PTTG1 protein in plasma of melanoma patients treated with BRAFi or the combination of dabrafenib plus trametinib.

Figure 8

PTTG1 levels were determined by ELISA in plasma samples of 16 responder (A) and 6 non-responder (B) melanoma patients before the start of therapy (T0), after two months of treatment (T2) and at disease progression (TP). Two patients among responders (case #13 and case #14) and 1 patient among non-responder (case #18) displayed PTTG1 plasma levels below the detection limit of the assay at all the time points analyzed and were not included in the figures. Each value represents the arithmetic mean ± SEM of two independent determinations. **P < 0.01 and *P < 0.05 T2 vs T0; §§P < 0.01 and §P < 0.05 TP vs T2.